Piper Sandler Reiterates Overweight Rating on BioCryst Pharma (BCRX)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- US stocks close down as oil spikes 12%, job market weakens
- U.S. nonfarm payroll employment unexpectedly falls in February
- Oracle stock falls on report of scrapped Texas data center plans
- Kuwait cuts oil output as storage fills up
- Boeing reportedly nearing 500-aircraft deal with China ahead of Trump visit
- After-hours movers: Marvell, Samsara, GAP, Cooper Cos.
- After-hours movers: Broadcom, StubHub, Cracker Barrel, Grocery Outlet, Veeva Systems and more
- After-hours movers: Moderna, CrowdStrike, Ross Stores, Box and more
- After-hours movers: MongoDB, Credo, SoFi Technologies and more
- After-hours movers: Dell, Block, CoreWeave, Autodesk, MARA and more
JPMorgan Reiterates Overweight Rating on BioCryst Pharma (BCRX)
February 24, 2025 8:58 AM UTCJPMorgan analyst Jessica Fye reiterated an Overweight rating and $10.00 price target on BioCryst Pharma (NASDAQ: BCRX)
The analyst comments "We think the ~3% upward guidance revision to FY25 Orladeyo revs by ~$18mm at the midpoint to $535-$550mm (vs prior guidance of $515-$535mm established earlier this year at our healthcare conference) will be well received as it supports 24% growth YoY for Orladeyo at the midpoint after 34% Orladeyo growth in 24. Well listen... More
BioCryst Pharma (BCRX) Misses Q4 EPS by 6c; offers outlook
February 24, 2025 7:29 AM UTCBioCryst Pharma (NASDAQ: BCRX) reported Q4 EPS of ($0.13), $0.06 worse than the analyst estimate of ($0.07). Revenue for the quarter came in at $131.53 million versus the consensus estimate of $127.17 million.
OUTLOOK
Financial Outlook for 2025
Based on the early... More
